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ABSTRACT
Between 1999 and 2001, 355 hospital laboratories
in Italy were asked to complete a questionnaire
addressing mycobacterial test methods, 1-year
workloads and laboratory safety features. Analy-
sis of the data showed that rapid methods for
mycobacterial testing were being used by most
larger laboratories; however, sub-optimal meth-
ods were still in use in small and medium-size
laboratories. In a country such as Italy, which has
a low prevalence of tuberculosis cases, imple-
mentation of rapid technologies, combined with
regionalisation of mycobacterial diagnostic servi-
ces, seems to be the most reasonable and cost-
effective strategy.
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Tuberculosis (TB) may be considered a global
emergency, with > 2 million people dying and 8
million new cases each year [1]. Although the
prevalence of TB in the industrialised world is
relatively low, outbreaks caused by multiresistant
strains of the Mycobacterium tuberculosis complex
(MTB) have occurred in hospitals, prisons and
shelters for homeless people, often involving
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HIV-infected individuals and immigrants [2]. To
control the spread of disease, individuals with TB
must be detected as quickly as possible and
placed on effective chemotherapy [3]. Conse-
quently, laboratories must adopt methods that
provide rapid and accurate detection, isolation,
identification and drug susceptibility testing
(DST) of MTB in clinical specimens [4,5]. This
issue has already been addressed in the USA
[6–9]. The present report describes the results of a
questionnaire developed by the Mycobacteria
Committee (CoSMic) of the Italian Association of
Clinical Microbiology (AMCLI) to assess current
practice in hospital clinical laboratories in Italy
that perform mycobacterial testing.
The Italian national health service is governed
at two political levels: nationally by the Parlia-
ment, and regionally by elected councils. Italy
comprises 20 regions whose councils implement
the health system locally through regional laws,
and who are also responsible for planning,
financing, monitoring and control [10]. In this
context, regional health institutions (Assessorati
alla Sanita`) were asked to co-manage the survey
and provide institutional coverage. Some regions
supported the survey actively, while others
unfortunately did not. Consequently, the survey
was completed over a 3-year period (1999–2001)
by the AMCLI regional offices. The laboratory
component covered the 12-month period (from 1
January to 31 December) closest to the data
collection.
The questionnaire requested information on
methods used for acid-fast microscopy, decon-
tamination, routine culture, species identification,
DST and reporting, as well as details of safety
equipment. Each laboratory was also asked to
indicate the number of samples processed, num-
ber of referred mycobacterial isolates, number of
MTB strains identified, number of isolates tested
for drug susceptibility, and whether novel
molecular amplification-based systems for direct
detection were being used. Information was
returned from AMCLI regional offices to the
CoSMic-appointed survey coordinator. Data were
coded, entered and analysed with the use of
either Epi Info 5.0 or Microsoft Excel software
packages.
Information was available for 355 (59.6%) of
596 public hospital laboratories contacted (inclu-
ding two regional reference laboratories), but the
response varied by region. Of the 20 regions, all
hospital-based laboratories were surveyed in ten
regions, 60–90% in four regions, and 30–50% in
four regions; in two regions, the survey could not
be performed at all. However, even in those
regions where coverage was not 100%, all the
largest laboratories were included.
Microscopy for acid-fast bacilli (AFB) was
performed by all laboratories, primary culture
by 298 (83.9%), identification of MTB by 133
(37.5%), DST by 83 (23.4%), and direct amplifi-
cation by 73 (20.6%). Larger hospital laboratories
were more likely to perform multiple mycobacte-
riology procedures. The total numbers of speci-
mens processed for microscopy for AFB and
culture during the surveyed 12-month interval
were 242 381 and 218 991, respectively; thus, even
though the sensitivity of smear microscopy is low,
> 23 000 specimens were not cultured for AFB.
In total, 179 (50.4%) laboratories processed
£ 500 clinical specimens ⁄ year, 105 (29.6%) labor-
atories processed 500–3000 clinical speci-
mens ⁄ year, and only 14 (3.9%) laboratories
processed > 3000 specimens ⁄year. Of the 57
(16.1%) laboratories that did not perform culture
for AFB, 35 (9.9%) sent specimens to larger
laboratories. The laboratories processing < 500
specimens ⁄year seemed to be located mostly in
central and southern Italy. MTB identification and
DST were performed on 10 045 and 5649 isolates,
respectively. In total, 22 740 MTB direct amplifi-
cation tests were performed during a 12-month
period, with 2723 (11.9%) positive results. Further
information concerning the methods used by
different laboratories is listed in Tables 1 and 2.
On average, results of smear microscopy for AFB
were available 3 days after specimen receipt
Table 1. Procedures used for smear detection and culti-
vation of mycobacteria in Italian laboratories
Test method No. (%) of laboratories
Smear microscopy stains
Ziehl–Neelsen 289 (81.4)
Fluorochrome 51 (14.4)
Kinyoun 15 (4.2)
Decontamination
Standard NALC–NaOH [18] 166 (55.7)
NALC–NaOH 3% v ⁄v 5 (1.7)
Dithiothreitol–NaOH 2% v ⁄v 8 (2.7)
NaOH 4% v ⁄v 24 (8.1)
Trisodium phosphate 15 (5.0)
Others 80 (26.8)
Primary culture medium
Solid 141 (47.3)
Solid and radiometric 18 (6.0)
Solid and non-radiometric 139 (46.7)
NALC, N-acetyl-l-cysteine.
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(mean times of 2.6, 2.9 and 3.5 days for northern,
central and southern Italy, respectively).
Of the 317 hospital laboratories that provided
information on biosafety measures [11,12], 107
(33.7%) reported a dedicated room or an isolation
room, and four (1.3%) had negative air ventila-
tion equipment. HEPA filter-equipped biological
safety cabinets were used in 269 (84.8%) laborat-
ories, while a centrifuge dedicated to procedures
for AFB was used in 117 (36.9%) laboratories.
However, only 146 (46.1%) centrifuges used for
mycobacterial testing were equipped with sealed
O-ring carriers. For decontamination, 55.7% of
laboratories used the standard n-acetyl-l-cysteine
(NALC)–NaOH method, with variations on the
most widely used protocol being used in many
other laboratories. Unfortunately, most of these
variations are considered to be harsh decontam-
ination systems that may significantly reduce the
number of viable mycobacteria.
The American Thoracic Society [13] has sug-
gested that, in order to maintain proficiency,
laboratories should process 10–15 speci-
mens ⁄week and identify 20 cultures ⁄week. Fewer
than 20% of surveyed laboratories in Italy can
fulfil these criteria. These findings suggest a need
for increased referral of samples and ⁄ or isolates
to larger laboratories, or the grouping together of
low-volume laboratories. Such a strategy would
reduce the risk of false-positive cultures, which is
associated significantly with laboratories dealing
with a low sample load [14], and would fit well
with the regional government network in Italy.
The major weakness of the survey was the
3-year data collection period and the uneven
response rate of hospital laboratories, but the
surveyed laboratories were representative (in
number and size) of the current Italian situation.
A previous Italian survey [15] of 99 clinical
laboratories located in larger hospitals (all inclu-
ding infectious diseases units) found that 57.6%
did not identify MTB and 42.6% did not perform
any DST. The biosafety picture was similar, in
that 15.1% of the laboratories did not use a Class
II safety cabinet, and 28% used unsealed-rotor
centrifuges.
In order to make the laboratory diagnosis of TB
in Italy more rapid, sensitive and safer for labor-
atory personnel, it seems advisable to concentrate
the diagnostic service in a limited number of
specialised laboratories, chosen on the basis of
workload and professional expertise. Factors
affecting the efficiency of reference laboratories
should also be addressed [6–9,16]. The American
Thoracic Society has recommended the classifica-
tion of laboratories into Levels I, II and III,
according to workload and expertise. Level II
should serve 1 million people (a regional reference
laboratory) and Level III should serve 5–10 million
people (a national reference laboratory). In Italy,
this structure of laboratory services was intro-
duced in 1998 by a national law (Guidelines for TB
control) [17], but only a minority of regions have
so far provided implementation plans, regional
laws and proper financial support. Regrettably, it
seems that much remains to be done by Italian
public health institutions to ensure that hospital
diagnostic laboratories are properly equipped and
prepared for mycobacteriology testing.
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ABSTRACT
This report describes the characterisation of a
mycobacterium involved in a case of septic arth-
ritis in an AIDS patient that was treated success-
fully with specific anti-mycobacterial drugs. The
biochemical and cultural features, and the mycolic
acid pattern as assessed by high-performance
liquid chromatography, were fully compatible
with the isolate being Mycobacterium flavescens.
However, the isolate’s 16S rDNA sequence dif-
fered by five nucleotides from the two known
sequevars of M. flavescens, thus indicating that this
isolate belonged to a new 16S rDNA sequevar.
Keywords AIDS, identification, Mycobacterium flaves-
cens, 16S rDNA
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Mycobacterium flavescens is a scotochromogenic
mycobacterium, characterised by an intermediate
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